[go: up one dir, main page]

WO2011122815A3 - Novel quinoxaline derivatives - Google Patents

Novel quinoxaline derivatives Download PDF

Info

Publication number
WO2011122815A3
WO2011122815A3 PCT/KR2011/002115 KR2011002115W WO2011122815A3 WO 2011122815 A3 WO2011122815 A3 WO 2011122815A3 KR 2011002115 W KR2011002115 W KR 2011002115W WO 2011122815 A3 WO2011122815 A3 WO 2011122815A3
Authority
WO
WIPO (PCT)
Prior art keywords
glp
receptor
regulating
quinoxaline derivatives
novel quinoxaline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/002115
Other languages
French (fr)
Other versions
WO2011122815A2 (en
Inventor
Ho-Sang Moon
Jae-Sung Yang
Mi-Kyung Kim
Jin-Kwan Kim
Jae-Young Lee
So-Mi Kang
Ha-Dong Kim
Chang-Yell Shin
Ye-Hwang Cheong
Eun-Kyoung Yang
Song-Hyen Choi
Young-Soo Park
Eun-Jung Kim
Yu-Na Chae
Eun-Jung Cho
Moon-Ho Son
Soon-Hoe Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong A Pharmaceutical Co Ltd
Original Assignee
Dong A Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110026747A external-priority patent/KR20110109917A/en
Application filed by Dong A Pharmaceutical Co Ltd filed Critical Dong A Pharmaceutical Co Ltd
Publication of WO2011122815A2 publication Critical patent/WO2011122815A2/en
Publication of WO2011122815A3 publication Critical patent/WO2011122815A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to a novel compound represented by the following Chemical Formula 1, a process for preparing it, and its pharmaceutically approved salt comprising it as an active ingredient. The compound of this invention is GLP 1 receptor regulating low molecular weight compound useful for treatment of metabolic diseases such as diabetes and obesity by regulating the function of glucagon like peptide 1 receptor (GLP 1 receptor) for the disease or disorder carried by GLP 1 since it has the effects on a drop of blood sugar and an improvement of insulin resistance.
PCT/KR2011/002115 2010-03-29 2011-03-28 Novel quinoxaline derivatives Ceased WO2011122815A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0028181 2010-03-29
KR20100028181 2010-03-29
KR10-2011-0026747 2011-03-25
KR1020110026747A KR20110109917A (en) 2010-03-29 2011-03-25 New Quinoxaline Derivatives

Publications (2)

Publication Number Publication Date
WO2011122815A2 WO2011122815A2 (en) 2011-10-06
WO2011122815A3 true WO2011122815A3 (en) 2012-03-08

Family

ID=44712733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002115 Ceased WO2011122815A2 (en) 2010-03-29 2011-03-28 Novel quinoxaline derivatives

Country Status (1)

Country Link
WO (1) WO2011122815A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
EP3060557A1 (en) 2013-10-23 2016-08-31 Bayer CropScience Aktiengesellschaft Substituted quinoxaline derivatives as pest control agent
WO2017072039A1 (en) 2015-10-26 2017-05-04 Bayer Cropscience Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
WO2020110152A1 (en) * 2018-11-29 2020-06-04 Girdhar Khyati Non-peptidic glucagon-like peptide-1 receptor agonists and method of preparation thereof
CN110950816B (en) * 2019-12-13 2021-07-06 山东金城医药化工有限公司 Synthesis method of 1- (2-dimethylaminoethyl) -5-mercaptotetrazole
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997535A (en) * 1973-03-16 1976-12-14 Allen & Hanburys Limited Quinoxaline-2-carboxamidotetrazoles
US20040116437A1 (en) * 1998-12-17 2004-06-17 Wyeth 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives
US20060142294A1 (en) * 2004-12-29 2006-06-29 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997535A (en) * 1973-03-16 1976-12-14 Allen & Hanburys Limited Quinoxaline-2-carboxamidotetrazoles
US20040116437A1 (en) * 1998-12-17 2004-06-17 Wyeth 2,3,4,4a-tetrahydro-1H-pyrazino(1,2-a) quinoxalin-5(6H)one derivatives
US20060142294A1 (en) * 2004-12-29 2006-06-29 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function

Also Published As

Publication number Publication date
WO2011122815A2 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
WO2011122815A3 (en) Novel quinoxaline derivatives
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
WO2013092703A3 (en) Glucagon analogues
MX336412B (en) Novel glucagon analogues.
EA021275B9 (en) Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease
WO2008103354A3 (en) Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
WO2009054423A1 (en) Oxadiazolidinedione compound
WO2010122980A8 (en) NOVEL THYROID HORMONE β RECEPTOR AGONIST
EP4325520A3 (en) System coordinator and modular architecture for open-loop and closed-loop control of diabetes
CL2007002347A1 (en) COMPOUNDS DERIVED FROM PHENYLL, PYRIDINE AND QUINOLINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF MELLITUS DIABETES, DISORDERS IN THE TOLERANCE OF GLUCOSE, OBESITY, CROHN'S DISEASE, SICK
CA2729938A1 (en) New insulin analogues of prolonged activity
WO2012009258A3 (en) Peptidomimetic galanin receptor modulators
PH12012501456A1 (en) Novel 3-hydroxy -5- arylisothiazole derivative
BR112015010314A8 (en) compound or pharmaceutically acceptable salts or isomers thereof, pharmaceutical composition, insulin secretagogue or hypoglycemic agent, gpr40 receptor agonist, and, method of treating diseases or disorders
WO2012011752A3 (en) Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
MY159058A (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
MY181731A (en) Azole benzene derivative
MX357780B (en) Polycyclic derivatives, preparation method and medical uses thereof.
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2012010966A3 (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11762987

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11762987

Country of ref document: EP

Kind code of ref document: A2